Compare ICFI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | ANIP |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2006 | 1999 |
| Metric | ICFI | ANIP |
|---|---|---|
| Price | $69.08 | $79.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $99.25 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 381.0K | 330.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 1.12 | ★ 1.28 |
| Revenue | ★ $1,229,162,000.00 | $206,547,000.00 |
| Revenue This Year | $4.12 | $21.01 |
| Revenue Next Year | $5.33 | $17.59 |
| P/E Ratio | ★ $61.72 | $63.35 |
| Revenue Growth | ★ 3.72 | 2.47 |
| 52 Week Low | $58.83 | $58.70 |
| 52 Week High | $101.71 | $99.50 |
| Indicator | ICFI | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 45.94 |
| Support Level | $64.43 | $77.03 |
| Resistance Level | $75.03 | $83.58 |
| Average True Range (ATR) | 3.10 | 2.65 |
| MACD | 0.46 | -0.21 |
| Stochastic Oscillator | 78.89 | 38.47 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.